erlotinib hydrochloride has been researched along with n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide) | Trials (n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide) | Recent Studies (post-2010) (n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 102 | 19 | 98 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0206 | |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | 0.0133 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.1445 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, DB; Kawashima, J; Koczywas, M; Kong, S; Kowalski, M; Neal, JW; Padda, SK; Reckamp, KL; Wakelee, HA | 1 |
1 trial(s) available for erlotinib hydrochloride and n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
| Article | Year |
|---|---|
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2022 |